A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
BeOne Medicines
National Institutes of Health Clinical Center (CC)
Ensem Therapeutics
St. Jude Children's Research Hospital
Eisai Inc.
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Peking Union Medical College Hospital
University of Southern California
NeoImmuneTech
University of Pennsylvania
Revolution Medicines, Inc.
BioNTech SE
Astellas Pharma Inc
Baptist Health South Florida
University of Chicago
Merck Sharp & Dohme LLC
Eli Lilly and Company
MBrace Therapeutics
Eisai Inc.
Replimune Inc.
Inmune Bio, Inc.
Corcept Therapeutics
Sichuan Enray Pharmaceutical Sciences Company
Lokon Pharma AB
Bristol-Myers Squibb
Children's Hospital of Philadelphia
AbbVie
Dana-Farber Cancer Institute
A2 Biotherapeutics Inc.
Merck Sharp & Dohme LLC
Immatics US, Inc.
Essen Biotech
Essen Biotech
AbbVie